Cantor Fitzgerald Gives a Buy Rating to Radius Health

By Ryan Adsit

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Radius Health (NASDAQ: RDUS) today and set a price target of $65. The company’s shares opened today at $40.

Goldstein commented:

“RDUS shares are trading down 8% intraday on the news of PDUFA extension for abaloparatide-SC, to June 30 from March 30, based on additional information (though not new data) submitted in support of the NDA.”

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 4.3% and a 47.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Cascadian Therapeutics.

Currently, the analyst consensus on Radius Health is Moderate Buy and the average price target is $52.50, representing a 31.3% upside.

In a report issued on February 24, Canaccord Genuity also reiterated a Buy rating on the stock with a $85 price target.

The company has a one year high of $59.88 and a one year low of $28. Currently, Radius Health has an average volume of 700.8K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. a biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women health conditions. Its BA058 Injection product is a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein. The company also develops BA058 Microneedle Patch; RAD1901, a selective estrogen receptor modulator for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator. Its initial business was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003. Radius Health was founded on February 4, 2008 and is headquartered in Cambridge, MA.